Novartis came in as a result of the promise of using remestemcel treatment for ARDS at the height of the COVID pandemic, just before the FDA fast tracked its trials. Novartis came in to make big money from treating COVID, not to treat you children with ARDS. The later is where we are going and we have heard nothing recently about treatment for COVID caused ARDS. This was just a commercial decision by Novartis. No big deal. Remestemcel not being a miracle COVID treatment for COVID has been factored into the price for a long time. The price was double what it is now before the Novartis deal. There has been a lot of good news in the trials since.
That's why the price has not completely collapsed this morning.
The disappointment of getting disappointing news when all (bar the shorters) were hoping for a big announcement is understandable, but get some perspective everyone! The shorters will be having a wonderful time covering all their shorts. If you are silly enough to bale out now and feed the shorters - that's bad decisions making, not bad luck!!
Ann: Update on Novartis Agreement, page-188
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |